Bitcoin

Mainstream coverage will focus on the medical breakthrough, but for crypto this is a non-event unless it triggers a broader rotation out of risk-off positions into equities. Given that biotech/pharma is a separate sector, the capital flows are unlikely to shift meaningfully into or out of crypto based on this single development.

A new drug has been reported to functionally cure many hepatitis B virus infections, based on an article published in Science.